Adverse Events and Oncotargeted Kinase Inhibitors

Adverse Events and Oncotargeted Kinase Inhibitors gathers and evaluates data on adverse events associated with tyrosine kinase inhibitors (TKIs), a powerful anti-tumor drug class that has recently been introduced for human therapy. This book compiles a comprehensive safety profile of each TKI from experiences in official therapeutic indications, also exploring off-label exploratory investigations and postmarketing pharmaceutical surveillance databases.

A brief history of each drug’s development and submission is provided, along with a more detailed analysis of the mechanism(s) of action involved in therapeutic activity or related to the insurgence of specific adverse events. Early chapters focus on general characteristics of TKIs, typology, and classification of adverse events, while the final chapters analyze TKIs as AE inducers and classes of AEs by system or organ involvement.

This comprehensive resource compiles and critically reviews all of the relevant safety data for this class of drugs, with the goal of improving the understanding of pathogenesis and facilitating the prevention, monitoring, and management of these adverse events.

• Offers a unique and comprehensive publication on the adverse events associated with a new and fast-growing class of medicines
• Provides a systematic analysis of adverse events aimed at better prevention through understanding and offering insights for the development of safer drugs
• Uses practical guidelines to establish a leading reference on this class of drugs for educators, researchers, drug developers, clinicians, safety professionals, and more

Intended for pharmacologists, clinicians and specialists including oncologists, drug safety control officials and drug developers and producers who are working to find effective molecules with the lowest adverse effects profiles; academics involved in drug safety issues and public health professionals

Part I: General Aspects

1. Introduction
2. Protein and Lipid Kinases
3. Kinase Inhibitors
4. Adverse Events

Part II: Oncotargeted Kinase Inhibitors

5. Imatinib
6. Gefitinib
7. Erlotinib
8. Sorafenib
9. Sunitinib
10. Dasatinib
11. Lapatinib
12. Nilotinib
13. Pazopanib
14. Vandetanib
15. Vemurafenib
16. Crizotinib
17. Ruxolitinib
18. Axitinib
19. Bosutinib
20. Regorafenib
21. Cabozantinib
22. Ponatinib
23. Dabrafenib
24. Trametinib
25. Adatinib
26. Idelalisib
27. Ibrutinib

Part III: Overview

28. Kinase Inhibitors as Adverse Event Inducers
29. Kinase Inhibitors as Drug Class Events
30. Conclusion and Perspectives